- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT06914128
Ensimmäinen ihmisen tutkimus oppia, kuinka Safe Bay 3713372 on ja miten se toimii osallistujissa MTAP-deletoitujen kiinteiden kasvainten kanssa
Bay 3713372: n, uuden toisen sukupolven Prmt5-estäjän, ensimmäisen ihmisen turvallisuuden, siedettävyyden ja farmakokinetiikan, farmakodynamiikan ja alustavan kliinisen aktiivisuuden arvioimiseksi, osallistujilla, joilla on MTAP-deletoitu kiinteät kasvaimet.
The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferase 5 (PRMT5). This may kill the MTAP-deleted cancer cells while sparing the normal cells.
The main objective of this first-in-human study is to learn how safe BAY 3713372 is, how the body processes it, and how well it works in people with MTAP-deleted solid tumors.
For this, the researchers will study and analyze:
- the number of participants who have adverse events (AEs) after receiving different doses of BAY 3713372 and the AE's severity.
- the number of participants who experience dose-limiting toxicities (DLTs) after receiving different doses of BAY 3713372, the DLT's severity and how often they happened. A DLT is a pre-defined medical problem caused by a specific dose of a drug that is too severe to continue using that dose.
- the total amount of BAY 3713372 in participants' blood (also called AUC) over time after single and multiple doses.
- the highest level of BAY 3713372 in participants' blood (also called Cmax) after single and multiple doses.
Other than the main objective, researchers will also check for the number of participants who show a response to treatment and how long they live without the cancer getting worse.
The study participants will take part in one of the eight distinct groups or "intervention cohorts" of the study. The study will start with a dose escalation phase where distinct groups of participants will receive different doses of BAY 3713372 alone to find the dose that is deemed safe and works best for the participants. When this dose has been found, a larger number of participants will receive BAY 3713372 alone or with other treatments in a dose expansion phase.
Participants may take the study treatment as long as they benefit from the treatment without any severe medical problems.
Participants will visit the study site:
- at least twice before the treatment starts
- multiple times when they start taking the treatment
- once after 30 days of receiving the last dose and every 9 weeks after that until the cancer worsens, or the participant stops for any other reason
During the study, the doctors and their study team will:
- check participants' health by performing tests such as blood and urine tests, and checking heart health using an electrocardiogram
- check if the participants' cancer has grown and/or spread using computed tomography (CT) or magnetic resonance imaging (MRI) and, if needed, bone scan
- take tumor samples
The study doctors and their team will contact the participants every 3 months until 2 years after the last participant's last dose or the end of the study to learn about the participant's health.
Tutkimuksen yleiskatsaus
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 2
- Vaihe 1
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Bayer Clinical Trials Contact
- Puhelinnumero: 18888422937
- Sähköposti: clinical-trials-contact@bayer.com
Opiskelupaikat
-
-
North Holland
-
Amsterdam, North Holland, Alankomaat, 1066 CX
- Rekrytointi
- Nederlands Kanker Instituut
-
-
Provincie Groningen
-
Groningen, Provincie Groningen, Alankomaat, 9713 GZ
- Ei vielä rekrytointia
- Universitair Medisch Centrum Groningen (UMCG) - UMC Groningen Comprehensive Cancer Center
-
-
South Holland
-
Rotterdam, South Holland, Alankomaat, 3015 CE
- Rekrytointi
- Erasmus Medisch Centrum
-
-
-
-
New South Wales
-
Camperdown, New South Wales, Australia, 2050
- Rekrytointi
- Chris O'Brien Lifehouse
-
Concord, New South Wales, Australia, 2139
- Rekrytointi
- Concord Repatriation General Hospital (CRGH) (Concord Hospital) - Concord Cancer Centre
-
Epping, New South Wales, Australia, 3076
- Ei vielä rekrytointia
- Northern Hospital
-
Waratah, New South Wales, Australia, 2298
- Rekrytointi
- Calvary Mater Hospital Newcastle - Oncology
-
-
-
-
Antwerp
-
Antwerp, Antwerp, Belgia, 2650
- Rekrytointi
- Antwerp University Hospital | Oncology Department
-
-
East Flanders
-
Ghent, East Flanders, Belgia, 9000
- Rekrytointi
- Ghent University Hospital | Drug Research Unit Department
-
-
Flemish Brabant
-
Leuven, Flemish Brabant, Belgia, 3000
- Rekrytointi
- UZ Leuven Gasthuisberg - Pneumology Department
-
-
Liège
-
Liège, Liège, Belgia, 4000
- Rekrytointi
- Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman - Medical Oncology
-
-
-
-
Barcelona
-
Barcelona, Barcelona, Espanja, 08023
- Rekrytointi
- Hospital Hm Nou Delfos | Oncologia
-
Barcelona, Barcelona, Espanja, 08035
- Rekrytointi
- Hospital Universitari Vall D Hebron | Oncologia
-
-
Chartered Community of Navarre
-
Pamplona, Chartered Community of Navarre, Espanja, 31008
- Rekrytointi
- Clinica Universidad De Navarra | Pamplona | Oncologia
-
-
La Rioja
-
Logroño, La Rioja, Espanja, 26006
- Rekrytointi
- Hospital San Pedro | Oncologia
-
-
Madrid
-
Madrid, Madrid, Espanja, 28040
- Rekrytointi
- Hospital Universitario Fundacion Jimenez Diaz | Oncologia
-
Pozuelo de Alarcón, Madrid, Espanja, 28223
- Rekrytointi
- NEXT - Hospital Universitario Quironsalud Madrid | Oncologia
-
-
Málaga
-
Málaga, Málaga, Espanja, 29010
- Rekrytointi
- Hospital Universitario Virgen De La Victoria | Oncologia
-
-
Valencia
-
Valencia, Valencia, Espanja, 46010
- Ei vielä rekrytointia
- Hospital Clinico Universitario De Valencia | Oncologia
-
-
-
-
Friuli Venezia Giulia
-
Aviano, Friuli Venezia Giulia, Italia, 33081
- Rekrytointi
- Centro di Riferimento Oncologico di Aviano - Oncologia Medica e dei Tumori Immuno-Correlati
-
-
Lazio
-
Rome, Lazio, Italia, 00128
- Rekrytointi
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Fase I
-
Rome, Lazio, Italia, 00144
- Ei vielä rekrytointia
- I.F.O. Istituti Fisioterapici Ospitalieri - Sperimentazioni cliniche Fase 1 e Medicina di precisione
-
-
Lombardy
-
Milan, Lombardy, Italia, 20133
- Rekrytointi
- Fondazione IRCCS Istituto Nazionale dei Tumori - S. C. Oncologia Medica 1
-
Rozzano, Lombardy, Italia, 20089
- Rekrytointi
- Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japani, 466-8560
- Ei vielä rekrytointia
- Nagoya University Hospital
-
-
Osaka
-
Sakai, Osaka, Japani, 590-0197
- Rekrytointi
- Kindai University Hospital
-
-
Shizuoka
-
Sunto, Shizuoka, Japani, 411-8777
- Rekrytointi
- Shizuoka Cancer Center
-
-
Tokyo
-
Chuo-ku, Tokyo, Japani, 104-0045
- Rekrytointi
- National Cancer Center Hospital
-
Koto-ku, Tokyo, Japani, 135-8550
- Rekrytointi
- The Cancer Institute Hospital of JFCR
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kiina, 100142
- Rekrytointi
- Beijing Cancer Hospital - Oncology Department
-
Beijing, Beijing Municipality, Kiina, 101149
- Ei vielä rekrytointia
- Beijing chest hospital, Capital Medical University
-
-
Hubei
-
Wuhan, Hubei, Kiina, 430075
- Rekrytointi
- Tongji Hosp. of Tongji Med Coll, Huazhong Uni of Sci & Tech.
-
-
Jiangsu
-
Nanjing, Jiangsu, Kiina, 210029
- Ei vielä rekrytointia
- Jiangsu Provincial People's Hospital - The First Affiliated Hospital of Nanjing Medical University
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kiina, 310016
- Ei vielä rekrytointia
- Sir Run Run Shaw Hospital, Zhejiang Univ. School of Medicine - Oncology Department
-
-
-
-
Stockholm County
-
Stockholm, Stockholm County, Ruotsi, 171 76
- Rekrytointi
- Karolinska Universitetssjukhuset - Solna - Fas I-enheten Solna CKC
-
-
Västra Götaland County
-
Gothenburg, Västra Götaland County, Ruotsi, 413 46
- Ei vielä rekrytointia
- Sahlgrenska Universitetssjukhuset - Sahlgrenska Sjukhuset - Klinisk prövningsenhet Fas I/FIH
-
-
-
-
Singapore
-
Singapore, Singapore, Singapore, 119074
- Rekrytointi
- National University Hospital Medical Centre
-
Singapore, Singapore, Singapore, 168583
- Rekrytointi
- National Cancer Center Singapore - Oncology Department
-
Singapore, Singapore, Singapore, 217562
- Rekrytointi
- Icon Cancer Centre
-
-
-
-
Capital Region / Region Hovedstaden
-
Copenhagen, Capital Region / Region Hovedstaden, Tanska, 2100
- Rekrytointi
- Rigshospitalet Copenhagen University Hospital | Oncology Department
-
-
Region of Southern Denmark / Region Syddanmark
-
Odense, Region of Southern Denmark / Region Syddanmark, Tanska, 5000
- Rekrytointi
- Odense University Hospital | Svendborg Sygehus - Oncology Department
-
-
-
-
Olomouc Region
-
Olomouc, Olomouc Region, Tšekki, 779 00
- Rekrytointi
- Fakultní nemocnice Olomouc - Onkologická klinika
-
-
South Moravian
-
Brno, South Moravian, Tšekki, 602 00
- Rekrytointi
- Masarykova Univerzita - Masarykuv Onkologicky Ustav (MOU) - Klinika Komplexni Onkologicke Pece (KKOP)
-
-
-
-
Greater Manchester
-
Manchester, Greater Manchester, Yhdistynyt kuningaskunta, M20 4BX
- Rekrytointi
- The Christie Hospital | Experimental Cancer Medicine Team
-
-
Surrey
-
Sutton, Surrey, Yhdistynyt kuningaskunta, SM2 5PT
- Ei vielä rekrytointia
- The Royal Marsden (Surrey) | Oak Foundation Drug Development Unit
-
-
-
-
Alabama
-
Birmingham, Alabama, Yhdysvallat, 35233
- Ei vielä rekrytointia
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital
-
-
California
-
Duarte, California, Yhdysvallat, 91010
- Ei vielä rekrytointia
- City of Hope - Duarte Cancer Center
-
Los Angeles, California, Yhdysvallat, 90095
- Ei vielä rekrytointia
- UCLA Health Bowyer Oncology Center
-
San Francisco, California, Yhdysvallat, 94143
- Rekrytointi
- UCSF Helen Diller Medical Center at Parnassus Heights - Neurology
-
Stanford, California, Yhdysvallat, 94305
- Ei vielä rekrytointia
- Stanford University Medical Center - Neurology
-
-
Colorado
-
Aurora, Colorado, Yhdysvallat, 80045
- Ei vielä rekrytointia
- UCHealth Cancer Center - Anschutz Medical Campus - University of Colorado Cancer Center
-
Denver, Colorado, Yhdysvallat, 80218
- Rekrytointi
- Sarah Cannon Research Institute at HCA HealthONE Presbyterian St. Luke's
-
-
Florida
-
Orlando, Florida, Yhdysvallat, 32827
- Rekrytointi
- Sarah Cannon Research Institute at Florida Cancer Specialists- Lake Nona
-
-
Massachusetts
-
Boston, Massachusetts, Yhdysvallat, 02215
- Ei vielä rekrytointia
- Dana-Farber Cancer Institute - Oncology Department
-
Boston, Massachusetts, Yhdysvallat, 02114
- Rekrytointi
- Massachusetts General Hospital - Neurology
-
-
Michigan
-
Grand Rapids, Michigan, Yhdysvallat, 49546
- Rekrytointi
- START | Midwest
-
-
New York
-
New York, New York, Yhdysvallat, 10065
- Rekrytointi
- Memorial Sloan Kettering Cancer Center New York - Main Campus
-
New York, New York, Yhdysvallat, 10029
- Rekrytointi
- Icahn School of Medicine at Mount Sinai - Oncology
-
-
Tennessee
-
Nashville, Tennessee, Yhdysvallat, 37203
- Rekrytointi
- SCRI Oncology Partners
-
-
Texas
-
Irving, Texas, Yhdysvallat, 75039
- Rekrytointi
- NEXT Dallas - Oncology Department
-
San Antonio, Texas, Yhdysvallat, 78229
- Rekrytointi
- START | San Antonio
-
-
Wisconsin
-
Milwaukee, Wisconsin, Yhdysvallat, 53226
- Ei vielä rekrytointia
- Froedtert Hospital - Clinical Cancer Center
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Participant must be ≥ 18 years old of age, or the legal age of consent in the jurisdiction of the country in which the study takes place, at the time of signing the informed consent.
- At least one measurable lesion that would qualify as target lesion by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1).
- Homozygous MTAP-deletion identified through molecular testing from a locally certified laboratory.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Exclusion Criteria:
-
Previous additional cancer other than the one evaluated in this study within the past 2 years except for basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, superficial bladder tumors, localized prostate cancer or other tumors that in the opinion of the investigator, are considered cured or not immediately life-threatening, and will not interfere with the scientific goals of this study.
-
A marked prolongation of QT/QTc interval at screening (e.g., repeated demonstration of a QTc interval >450 ms). Participants with permanent pacemakers (i.e., a paced rhythm) may be eligible based on the investigator's clinical assessment and discretion.
-
Cardiac history comprising:
- History of congestive heart failure Class >II according to the New York Heart Association Functional Classification.
- Myocardial infarction less than 6 months before the start of study intervention.
- Serious cardiac arrhythmias requiring treatment or any clinically important abnormalities in rhythm, conduction or morphology on resting ECG with the exception of atrial fibrillation which is well-controlled and requires only digoxin or beta blockers.
-
Unstable angina within 4 weeks before start of study intervention.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei satunnaistettu
- Inventiomalli: Peräkkäinen tehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Dose Escalation (Intervention Cohort 1)
For the escalation part, different dose levels of BAY 3713372 administered as monotherapy are planned. |
Daily oral administration |
|
Kokeellinen: Backfill cohorts in Intervention Cohort 1 (Dose Escalation)
Backfill cohorts may be initiated concurrently with dose escalation cohorts to generate additional safety, pharmacokinetic, and pharmacodynamic data to facilitate the selection of the optimal doses for use in further development. |
Daily oral administration |
|
Kokeellinen: Dose Expansion (Intervention Cohort 1)
Dose expansion with BAY 3713372 monotherapy in selected participants with MTAP-deleted solid tumors. |
Daily oral administration |
|
Kokeellinen: Dose Expansion (Intervention Cohort 2)
Dose expansion with BAY 3713372 monotherapy in participants with MTAP-deleted non-small cell lung cancer (NSCLC). |
Daily oral administration |
|
Kokeellinen: Dose Expansion (Intervention Cohort 3)
Dose expansion with BAY 3713372 in combination with other treatments in participants with MTAP-deleted NSCLC. |
Daily oral administration |
|
Kokeellinen: Dose Expansion (Intervention Cohort 4)
Dose expansion with BAY 3713372 in combination with other treatments in participants with MTAP-deleted NSCLC. |
Daily oral administration |
|
Kokeellinen: Dose Expansion (Intervention Cohort 5)
Dose expansion with BAY 3713372 monotherapy in participants with MTAP-deleted pancreatic ductal adenocarcinoma (PDAC). |
Daily oral administration |
|
Kokeellinen: Dose Expansion (Intervention Cohort 6)
Dose expansion with BAY 3713372 in combination with other treatments in participants with MTAP-deleted PDAC. |
Daily oral administration |
|
Kokeellinen: Window-of-opportunity trial in participants with MTAP-deleted GBM (Intervention Cohort 7)
A surgical window-of-opportunity trial of BAY 3713372 alone in participants with MTAP-deleted glioblastoma (GBM). |
Daily oral administration |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Annoksen kärjistyminen (Master and Intervention kohortti 1): LAA 3713372: n vastaavan annosteluvälin maksimipitoisuus (CMAX)
Aikaikkuna: Ensimmäisestä tutkimuksen intervention annoksesta sykliin 2 päivään 1 (jokainen sykli on 21 päivää)
|
Ensimmäisestä tutkimuksen intervention annoksesta sykliin 2 päivään 1 (jokainen sykli on 21 päivää)
|
|
|
Annoksen kärjistyminen (isäntä- ja interventiokohortti 1): Alue Bayn 3713372 vastaavan annosteluvälin alla (AUC) alla (AUC)
Aikaikkuna: Ensimmäisestä tutkimuksen intervention annoksesta sykliin 2 päivään 1 (jokainen sykli on 21 päivää)
|
Ensimmäisestä tutkimuksen intervention annoksesta sykliin 2 päivään 1 (jokainen sykli on 21 päivää)
|
|
|
Dose Escalation (Master and Intervention Cohort 1): Number of participants with treatment-emergent adverse events (TEAEs)
Aikaikkuna: From the first administration of study intervention up to 30 days after the last dose of study intervention
|
TEAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary |
From the first administration of study intervention up to 30 days after the last dose of study intervention
|
|
Dose Escalation (Master and Intervention Cohort 1): Number of participants with treatment-emergent serious adverse events (TESAEs)
Aikaikkuna: From the first administration of study intervention up to 30 days after the last dose of study intervention
|
TESAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary |
From the first administration of study intervention up to 30 days after the last dose of study intervention
|
|
Dose Escalation (Master and Intervention Cohort 1): Severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)
Aikaikkuna: From the first administration of study intervention up to 30 days after the last dose of study intervention
|
TEAEs and TESAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary |
From the first administration of study intervention up to 30 days after the last dose of study intervention
|
|
Dose Escalation (Master and Intervention Cohort 1): Incidence of dose-limiting toxicities (DLTs)
Aikaikkuna: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)
|
DLTs per participants. DLTs will be graded according to NCI-CTCAE v.5.0 |
From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)
|
|
Dose Escalation (Master and Intervention Cohort 1): Number of participants with DLTs
Aikaikkuna: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)
|
Number of participants with at least one DLT |
From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)
|
|
Dose Expansion (Master, Intervention Cohorts 1 - 6): Objective response rate (ORR)
Aikaikkuna: Approximately 1.5 years
|
Determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) |
Approximately 1.5 years
|
|
Dose Expansion (Intervention Cohorts 3, 4 and 6): Number of participants with DLTs
Aikaikkuna: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days, except for Intervention Cohort 6, which has a cycle length of 28 days)
|
Number of participants with at least one DLT |
From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days, except for Intervention Cohort 6, which has a cycle length of 28 days)
|
|
Intervention Cohort 7: Number of participants with treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)
Aikaikkuna: From the first administration of study intervention up to 30 days after the last dose of study intervention
|
TEAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary |
From the first administration of study intervention up to 30 days after the last dose of study intervention
|
|
Intervention Cohort 7: Severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)
Aikaikkuna: From the first administration of study intervention up to 30 days after the last dose of study intervention
|
TEAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary |
From the first administration of study intervention up to 30 days after the last dose of study intervention
|
|
Intervention Cohort 7: Number of participants with DLTs
Aikaikkuna: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)
|
Number of participants with at least one DLT |
From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)
|
|
Intervention Cohort 7: Brain and brain tumor PK concentration of BAY 3713372
Aikaikkuna: From first dose through day of surgery (approximately 7 ± 2 days)
|
Concentration of BAY 3713372 in enhancing and non-enhancing brain tumor tissue obtained at definitive surgery, with corresponding time-matched plasma concentrations and estimation of tumor-to-plasma exposure ratios |
From first dose through day of surgery (approximately 7 ± 2 days)
|
|
Intervention Cohort 7: Tumor tissue SDMA levels
Aikaikkuna: From first dose through day of surgery (approximately 7 ± 2 days)
|
Change in symmetric dimethylarginine (SDMA) levels in brain tumor tissue collected at definitive surgery following neoadjuvant BAY 3713372 treatment, as a pharmacodynamic marker of PRMT5 inhibition |
From first dose through day of surgery (approximately 7 ± 2 days)
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Annoksen kärjistyminen (Master and Intervention kohortti 1): Aika vaste (TTR)
Aikaikkuna: Noin 1,5 vuotta
|
Noin 1,5 vuotta
|
|
|
Annoslaajennus (Master, interventiokohortit 1 - 6): Aika vaste (TTR)
Aikaikkuna: Noin 1,5 vuotta
|
Noin 1,5 vuotta
|
|
|
Annoksen laajennus (Master, interventiokohortit 1 - 4 ja 6): BAY 3713372: n vastaavan annosteluvälin maksimaalinen pitoisuus (CMAX) (CMAX)
Aikaikkuna: Ensimmäisestä tutkimuksen intervention annoksesta sykliin 2 päivään 1 (jokainen sykli on 21 päivää, paitsi interventiokohortti 6, jonka syklin pituus on 28 päivää)
|
Ensimmäisestä tutkimuksen intervention annoksesta sykliin 2 päivään 1 (jokainen sykli on 21 päivää, paitsi interventiokohortti 6, jonka syklin pituus on 28 päivää)
|
|
|
Annoksen laajennus (pää, interventiokohortit 1 - 4 ja 6): Bayn 3713372 vastaavan annosteluvälin käyrän (AUC) alaosa (AUC)
Aikaikkuna: Ensimmäisestä tutkimuksen intervention annoksesta sykliin 2 päivään 1 (jokainen sykli on 21 päivää, paitsi interventiokohortti 6, jonka syklin pituus on 28 päivää)
|
Ensimmäisestä tutkimuksen intervention annoksesta sykliin 2 päivään 1 (jokainen sykli on 21 päivää, paitsi interventiokohortti 6, jonka syklin pituus on 28 päivää)
|
|
|
Dose Expansion (Part A of Intenvention Cohort 2): Time to CNS progression (CNS-TTP)
Aikaikkuna: Approximately 3 years
|
Approximately 3 years
|
|
|
Dose Expansion (Part B of Intervention Cohort 2): CNS-related disease control rate (CNS-DCR) in active brain metastases
Aikaikkuna: Approximately 1.5 years
|
Approximately 1.5 years
|
|
|
Dose Escalation (Master and Intervention Cohort 1): Objective response rate (ORR)
Aikaikkuna: Approximately 1.5 years
|
Determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) |
Approximately 1.5 years
|
|
Dose Escalation (Master and Intervention Cohort 1): Duration of response (DOR)
Aikaikkuna: Approximately 3 years
|
Determined by the investigator according to RECIST v1.1 |
Approximately 3 years
|
|
Dose Escalation (Master and Intervention Cohort 1): Progression-free survival (PFS)
Aikaikkuna: Approximately 3 years
|
Determined by the investigator according to RECIST v1.1 |
Approximately 3 years
|
|
Dose Expansion (Master, Intervention Cohorts 1 - 6): Number of participants with treatment-emergent adverse events (TEAEs)
Aikaikkuna: From the first administration of study intervention up to 30 days after the last dose of study intervention
|
TEAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary |
From the first administration of study intervention up to 30 days after the last dose of study intervention
|
|
Dose Expansion (Master, Intervention Cohorts 1 - 6): Number of participants with treatment-emergent serious adverse events (TESAEs)
Aikaikkuna: From the first administration of study intervention up to 30 days after the last dose of study intervention
|
TESAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary |
From the first administration of study intervention up to 30 days after the last dose of study intervention
|
|
Dose Expansion (Master, Intervention Cohorts 1 - 6): Severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)
Aikaikkuna: From the first administration of study intervention up to 30 days after the last dose of study intervention
|
TEAEs and TESAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary |
From the first administration of study intervention up to 30 days after the last dose of study intervention
|
|
Dose Expansion (Master, Intervention Cohorts 1, 3, 4, and 6): Incidence of dose-limiting toxicities (DLTs)
Aikaikkuna: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days, except for Intervention Cohort 6, which has a cycle length of 28 days)
|
DLTs per participants. DLTs will be graded according to NCI-CTCAE v.5.0 |
From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days, except for Intervention Cohort 6, which has a cycle length of 28 days)
|
|
Dose Expansion (Master, Intervention Cohorts 1 - 6): Duration of response (DOR)
Aikaikkuna: Approximately 3 years
|
Determined by the investigator according to RECIST v1.1 |
Approximately 3 years
|
|
Dose Expansion (Master, Intervention Cohorts 1 - 6): Progression-free survival (PFS)
Aikaikkuna: Approximately 3 years
|
Determined by the investigator according to RECIST v1.1 |
Approximately 3 years
|
|
Dose Expansion (Part B of Intervention Cohort 2): CNS-ORR for active brain metastases
Aikaikkuna: Approximately 1.5 years
|
CNS-ORR: CNS objective response rate |
Approximately 1.5 years
|
|
Dose Expansion (Part B of Intervention Cohort 2): CNS-DOR for active brain metastases
Aikaikkuna: Approximately 3 years
|
CNS-DOR: Duration of CNS response |
Approximately 3 years
|
|
Dose Expansion (Part B of Intervention Cohort 2): CNS-PFS for active brain metastases
Aikaikkuna: Approximately 3 years
|
CNS-PFS: Survival without CNS progression |
Approximately 3 years
|
|
Dose Expansion (Part B of Intervention Cohort 2): CNS-TTR for active brain metastases
Aikaikkuna: Approximately 1.5 years
|
CNS-TTR: Time to CNS response |
Approximately 1.5 years
|
Yhteistyökumppanit ja tutkijat
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Neoplasmat sivustoittain
- Neoplasmat
- Hengityselinten sairaudet
- Neoplasmat histologisen tyypin mukaan
- Keuhkosairaudet
- Kasvaimet, rauhas- ja epiteelikasvaimet
- Hengitysteiden kasvaimet
- Rintakehän kasvaimet
- Keuhkojen kasvaimet
- Astrosytooma
- Glioma
- Neoplasmat, neuroepiteliaaliset
- Neuroektodermaaliset kasvaimet
- Neoplasmat, sukusolut ja alkiot
- Kasvaimet, hermokudos
- Syöpä, bronkogeeninen
- Keuhkoputkien kasvaimet
- Glioblastooma
- Karsinooma, ei-pienisoluinen keuhko
Muut tutkimustunnusnumerot
- 22931
- 2025-520623-24-00 (Rekisterin tunniste: CTIS (EU))
- 2025 (Yhdysvaltain NIH-apuraha/sopimus)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .